|
 |
 |
|
 |
|
|
We have entered into a capital alliance with
Fukuoka Oxygen Company. In addition, Kenshiro Fujisawa was appointed as the
representative director and president.
Thank you in the future. (September 1, 2022)
【Business Outline】
We are engaged in R&D and commercialization of gene diagnostic agents,
pharmaceutical materials,biosensors, and catalysts using DNA/RNA derivatives
as materials based on nucleic acid chemistry technology through joint studies
with research organizations, including universities.
【Products & Services】
■Products
・Nucleotide for gene amplification
We have realized high-quality, low-price “nucleotides for gene amplification”
using our original phosphorylation technology.
・Contract synthesis
In the “contract synthesis” business, we have a track record of producing
special nucleic acid compounds, including special nucleosides, nucleotides,
and oligonucleotides using our special technology.
■Commercialization Strategy
・Drug Discovery
We are carrying out research and product development of Small molecules
that target DNA/RNA.
|
|
|
|
